Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2025
Trends and outcomes for patients receiving neoadjuvant therapy for stage I to III gastric gastrointestinal stromal tumors.
СтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bennett Cade F, Janczewski Lauren M, Vitello Dominic, Wells Amy, Obeidin Farres, Alexiev Borislav A, Hayes John, Faruqi Fahad, Bentrem David, Wayne Jeffrey D, Abad John, Hardy Ashley, de Viverios Pedro Hermida, Pollack Seth M, Chawla Akhil
Аннотация
BACKGROUND: The use of neoadjuvant therapy (NAT) is not well characterized across the entire spectrum of localized gastrointestinal stromal tumors (GISTs). This study aimed to identify treatment trends for the use of NAT and survival outcomes in patients who underwent surgery for gastric GISTs.
METHODS: The National Cancer Database was queried to identify patients with stage I to III gastric GISTs between 2006 and 2020 who underwent curative-intent surgery after NAT or upfront surgery (UFS). The cohort demographics and cancer characteristics were compared using analysis of variance, generalized linear models, and chi-square analysis. Treatment trends were assessed using linear regression. Cox proportional hazards models and Kaplan-Meier curves were used for propensity score matching (3:1).
RESULTS: Between 2006 and 2020, 1504 patients (8.1%) received NAT, followed by surgery, and 17,150 patients (91.9%) received UFS with curative intent. The cohort analysis revealed that, compared with patients who underwent UFS, those who underwent NAT had higher grade tumors (P =.031), larger tumors (12.0 vs 6.4 cm, respectively; P <.001), and higher clinical staging (P <.01). Linear regression indicated that the use of NAT became more common each year (0.88%; P <.05) and that NAT was administered for longer durations before surgery (increase in 5.5 d/y; SE, 0.9; P <.05). Despite NAT being used for larger and higher-grade tumors, patients who underwent NAT had similar outcomes as those who underwent UFS (UFS: hazard ratio, 0.86 [95% CI, 0.76-1.01]; P =.07).
CONCLUSION: Our results demonstrate that the use of NAT has been increasing over time and that NAT is used for more advanced gastric GISTs. Although NAT is used for higher-risk tumors, its use for gastric GISTs leads to similar outcomes as UFS.
METHODS: The National Cancer Database was queried to identify patients with stage I to III gastric GISTs between 2006 and 2020 who underwent curative-intent surgery after NAT or upfront surgery (UFS). The cohort demographics and cancer characteristics were compared using analysis of variance, generalized linear models, and chi-square analysis. Treatment trends were assessed using linear regression. Cox proportional hazards models and Kaplan-Meier curves were used for propensity score matching (3:1).
RESULTS: Between 2006 and 2020, 1504 patients (8.1%) received NAT, followed by surgery, and 17,150 patients (91.9%) received UFS with curative intent. The cohort analysis revealed that, compared with patients who underwent UFS, those who underwent NAT had higher grade tumors (P =.031), larger tumors (12.0 vs 6.4 cm, respectively; P <.001), and higher clinical staging (P <.01). Linear regression indicated that the use of NAT became more common each year (0.88%; P <.05) and that NAT was administered for longer durations before surgery (increase in 5.5 d/y; SE, 0.9; P <.05). Despite NAT being used for larger and higher-grade tumors, patients who underwent NAT had similar outcomes as those who underwent UFS (UFS: hazard ratio, 0.86 [95% CI, 0.76-1.01]; P =.07).
CONCLUSION: Our results demonstrate that the use of NAT has been increasing over time and that NAT is used for more advanced gastric GISTs. Although NAT is used for higher-risk tumors, its use for gastric GISTs leads to similar outcomes as UFS.